Recombinant bispecific antibodies for cancer therapy.
Bispecific antibodies can serve as mediators to retarget effector mechanisms to disease-associated sites. Studies over the past two decades have revealed the potentials but also the limitations of conventional bispecific antibodies. The development of recombinant antibody formats has opened up the possibility of generating bispecific molecules with improved properties. This review summarizes recent developments in the field of recombinant bispecific antibodies and discusses further requirements for clinical development.
Kontermann
Roland E
RE
Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany. Roland.Kontermann@izi.uni-stuttgart.de
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology; D004355:Drug Stability; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D015202:Protein Engineering / Q000379:methods; D011994:Recombinant Proteins / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use
D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D011994:Recombinant Proteins